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Abstract
Objective: To compare characteristics and outcomes of women diagnosed with gestational
diabetes mellitus (GDM) by the newer one-step glucose tolerance test and those diagnosed
with the traditional two-step method.
Research design and methods: This was a retrospective cohort study of women with GDM who
delivered in 2010–2011. Data are reported as proportion ormedian (interquartile range) andwere
compared using a Chi-square, Fisher’s exact or Wilcoxon rank sum test based on data type.
Results: Of 235 women with GDM, 55.7% were diagnosed using the two-step method and 44.3%
with the one-step method. The groups had similar demographics and GDM risk factors. The
two-step method group was diagnosed with GDM one week later [27.0 (24.0–29.0) weeks
versus 26.0 (24.0–28.0 weeks); p¼ 0.13]. The groups had similar median weight gain per week
before diagnosis. After diagnosis, women in the one-step method group had significantly
higher median weight gain per week [0.67 pounds/week (0.31–1.0) versus 0.56 pounds/week
(0.15–0.89); p¼ 0.047]. In the one-step method group more women had suspected macrosomia
(11.7% versus 5.3%, p¼ 0.07) and more neonates had a birth weight44000 g (13.6% versus
7.5%, p¼ 0.13); however, these differences were not statistically significant. Other pregnancy
and neonatal complications were similar.
Conclusions: Women diagnosed with the one-step method gained more weight per week after
GDM diagnosis and had a non-statistically significant increased risk for suspected macrosomia.
Our data suggest the one-step method identifies women with at least equally high risk as the
two-step method.
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Introduction
The screening and diagnosis of gestational diabetes mellitus
(GDM) has been the subject of much recent discussion and
debate [1–6]. A number of studies have demonstrated that
increasing levels of carbohydrate intolerance, even in women
who were not diagnosed with GDM by customary criteria,
have been associated with increased frequency of maternal–
fetal complications [7–12]. Several other large randomized
studies have shown that more aggressively treating ‘‘mild’’
GDM results in lower rates of adverse neonatal and maternal
outcomes [13,14]. The Hyperglycemia and Adverse
Pregnancy Outcomes (HAPO) study [15] was an inter-
national, prospective study demonstrating a strong association
between increasing maternal glucose levels and maternal and
neonatal outcomes such as preeclampsia, cesarean delivery
and large for gestational age infants.
In response to these studies, in 2010 the International
Association of Diabetes in Pregnancy Study Groups
(IADPSG) [16] and in 2011 the American Diabetes
Association (ADA) [1] endorsed the use of universal 2-h
75-g oral glucose tolerance testing in pregnant women at 24 to
28 weeks of gestation (one-step method). Traditionally, most
pregnant women were screened for GDM using a 1-h 50-g
test, followed by a 3-h 100-g test if positive (two-step
method). In 2011, the American Congress of Obstetricians
and Gynecologists (ACOG) issued a Committee Opinion [2],
which concluded that the one-step method would increase the
incidence of a GDM diagnosis from approximately 8% to 18%
and likely would lead to an increase in health care costs
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without definitive evidence for improvement in maternal and
neonatal outcomes. This was reaffirmed in the ACOG
practice bulletin on gestational diabetes in August 2013 [3].
The National Institutes of Health (NIH) held a Consensus
Development Conference in March 2013, which also
concluded that there is insufficient evidence to recommend
the one-step method [4,5]. Later the same year, in contrast to
NIH and ACOG, the Endocrine Society recommended the
one-step method [6]. Even more recently, the ADA has stated
that either the one-step or two-step method is acceptable for
GDM screening [17].
Subsequent to the initial recommendations from IADPSG,
the Joslin Diabetes Center (JDC), a freestanding center, and
the academic obstetric practice at Beth Israel Deaconess
Medical Center (BIDMC), a large tertiary care facility,
decided to adopt the IADPSG guidelines recommended by
the HAPO study and the ADA. This practice was instituted in
December 2010 and has not been officially altered since the
recent ACOG and NIH recommendations.
Our objective was to compare characteristics and outcomes
of women diagnosed with GDM by the usual two-step method
(using the National Diabetes Data Group criteria) with those
diagnosed by the one-step IADPSG method. We aimed to
ascertain whether patient characteristics, pregnancy manage-
ment, pregnancy outcomes, and neonatal outcomes differed
based on which diagnostic method was used.
Research design and methods
This was a retrospective cohort study of women with GDM
and a singleton pregnancy who delivered at BIDMC from 1
January 2010 through 31 December 2011 and were seen in the
JDC and BIDMC Diabetes in Pregnancy Program for GDM
counseling and management. This allowed approximately one
year of deliveries prior to adoption of the one-step IADPSG
method and one year after. Throughout the study period, the
obstetrical and endocrinology providers and dietary counsel-
ing were similar. A survey of obstetric providers at BIDMC
revealed that 91% of the providers refer all the GDM patients
to the JDC and BIDMC Diabetes in Pregnancy Program,
indicating that the majority of GDM patients who deliver at
BIDMC were identified for this study. The institutional
review board at BIDMC approved this study.
We collected data from maternal and neonatal electronic
medical records, including demographic characteristics, med-
ical history, maternal weight before and during pregnancy,
GDM test results, and pregnancy management (GDM treat-
ment with diet with or without insulin and number of
ultrasounds). We also obtained data on pregnancy outcomes,
such as mode of delivery and maternal complications.
Neonatal outcomes examined included gestational age at
delivery, birth weight, need for NICU admission, hypogly-
cemia, hyperbilirubinemia, birth injury, clavicular fracture, or
brachial plexus injury. Neonatal hypoglycemia was defined as
at least one blood glucose less than 45 mg/dL. Neonatal
hyperbilirubinemia was defined as treatment with photother-
apy. Presence of clavicular fracture was assessed by review of
radiology reports, and brachial plexus injury was defined by
diagnosis of brachial plexus injury by attending neonatologist.
Any neonatal adverse outcome was defined as macrosomia
(birth weight44000 g), hypoglycemia, hyperbilirubinemia,
clavicle fracture, brachial plexus injury, or NICU admission.
Maternal weight within three months before pregnancy
was used to calculate pre-pregnancy body mass index (BMI)
and overall weight gain in pregnancy. If pre-pregnancy weight
was missing, the earliest weight in the first 12 weeks of
gestation was used. Data was stored in REDCap [18]. We
categorized BMI as normal (18.5 to525 kg/m2), overweight
(25.0 to530 kg/m2), or obese (30.0 kg/m2), adapted from
the WHO International Classification of normal, overweight,
and obese adults [19]. Risk factors for GDM included a strong
family history of diabetes (one first-degree relative or two
second-degree relatives); being overweight or obese; chronic
hypertension; polycystic ovary syndrome; being Asian, black
or Hispanic; and age 35 years [3].
All data were analyzed using SAS 9.3 (SAS Institute Inc.,
Cary, NC). All tests were two-sided and p50.05 was required
to confer significance. Comparisons were made using a
Chi-square or Fisher’s exact test for categorical variables and
the Wilcoxon rank sum test for continuous variables. Data are
reported as proportion or median (interquartile range).
Results
Of the 235 women who met eligibility criteria, 131 (55.7%)
were diagnosed with GDM using the two-step method, and
104 (44.3%) were diagnosed using the one-step method.
Before the one-step method was adopted, nearly all patients
(98.2%) were diagnosed using the two-step method. After the
new guidelines were adopted, 79.5% of the patients were
diagnosed using the one-step method and the rest (20.5%)
were diagnosed using the two-step method.
The two-step and one-step method groups were similar
with regard to the median age, median pre-pregnancy BMI
and medical history. Most (96.2%) of the patients in each
group diagnosed with GDM had one risk factor for GDM
(p¼ 0.10). Women in the one-step method group were more
likely to be primiparous, less likely to be non-Hispanic white,
and more likely to be Asian/Pacific Islander, although the
differences did not reach statistical significance. Table 1
shows the maternal characteristics of the two groups.
Women in the two-step method group were diagnosed with
GDM one week later in pregnancy than in the one-step
method group (p¼ 0.13; Table 2). Women in both groups had
a similar median weight gain per week before the GDM
diagnosis. After the GDM diagnosis, the patients in the one-
step method group had significantly higher median weight
gain per week compared with the two-step method group
(p¼ 0.047). The overall median weight gain per week was
also higher in the one-step method group compared with the
two-step method group (0.70 pounds/week, although this
difference was not statistically significant (p¼ 0.06)).
A similar proportion of the patients in each group was treated
with insulin as compared to managed with diet only. None of
the patients was managed using oral agents.
Both the groups delivered at a median of 39.0 weeks of
gestation. Approximately half of the patients in each group
delivered vaginally, and median birth weight was similar in
the two groups (p¼ 0.52). Patients in the one-step method
group had significantly more ultrasounds during pregnancy
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compared with patients in the two-step method group
(p¼ 0.003). There were more patients who had an ultrasono-
graphic suspicion of macrosomia in the one-step method
group (11.7% versus 5.3%, p¼ 0.07) and there were more
neonates with a birth weight44000 g in the one-step method
group (13.6% versus 7.5%, p¼ 0.13); however, these differ-
ences did not reach statistical significance. Other pregnancy
complications, neonatal complications, and neonatal intensive
care unit admission, as well as a composite measure of
adverse neonatal outcomes, were not significantly different
between the groups (all p 0.10; Table 3).
Conclusions
Our study aimed to ascertain whether women diagnosed with
GDM by the one-step IADPSG diagnostic method differed
from those diagnosed by the two-step method with regard to
patient characteristics, GDM treatment, and pregnancy and
neonatal outcomes. Aside from observed differences in parity
and race/ethnicity that were not statistically significant, the
baseline patient characteristics and risk factors for GDM were
similar in patients diagnosed with the two-step method
compared with the one-step method. With the exception of
slightly more weight gain per week after the GDM diagnosis
and more suspected macrosomia in the one-step method
group, pregnancy and neonatal outcomes did not differ based
on the method of GDM diagnosis. Patients were diagnosed
with GDM about a week earlier using the one-step method,
probably because the extra step of the one-hour screening test
was eliminated.
Although the incidence of cesarean delivery was similar
between the groups, the incidence in both the groups, near
50%, was higher than what was reported for singleton and
multiple gestations combined in the United States (32.8%)
[20] and at our institution (37% in 2010 and 36% in 2011)
during the same time period. Patients with GDM have been
reported to have a higher incidence of cesarean delivery [21];
thus, this is not unexpected due to the presence of co-
morbidities such as obesity and an increased risk for
macrosomia.
Weight gain prior to the diagnosis of GDM was not
different in the two groups. However, patients diagnosed
using the one-step method gained significantly more weight
per week, approximately a tenth of one pound, after the
diagnosis of GDM, despite similar pre-pregnancy BMIs. This
is unlikely to be a clinically significant increase in weight






Maternal age (years) 34.0 (32.0–37.0) 34.0 (30.0–38.0) 0.28
535 67 (51.1) 59 (56.7) 0.39
35 64 (48.9) 45 (43.3)
Body mass index before 12 weeks of gestation* 27.1 (23.2–32.5) 25.9 (22.5–31.6) 0.30
525 (normal or underweight) 41 (35.7) 38 (42.7) 0.59
25–30 (overweight) 31 (27.0) 22 (24.7)
 30 (obese) 43 (37.4) 29 (32.6)
Parity 0.06
Primiparous 52 (32.7) 54 (51.9)
Multiparous 79 (60.3) 50 (48.1)
Race/ethnicity 0.26
Non-Hispanic white 55 (42.0) 34 (32.7)
Non-Hispanic black 18 (13.7) 13 (12.5)
Hispanic 7 (5.3) 9 (8.7)
Asian/Pacific Islander 36 (27.5) 40 (38.5)
Other 15 (11.5) 8 (7.7)
Medical history
Family history of diabetes 61 (46.6) 50 (48.1) 0.82
Chronic hypertension 13 (9.9) 8 (7.7) 0.55
Polycystic ovary syndrome 6 (4.6) 10 (9.6) 0.13
Data are presented as median (interquartile range) or n (%).
*Data available for 115 (87.8%) women in the two-step method group and 89 (85.6%) women in the one-step
method group.





Gestational age at time of GDM diagnosis (weeks) 27.0 (25.0–29.0) 26.0 (24.5–28.0) 0.20
Weight gain per week prior to GDM diagnosis (pounds) 0.78 (0.53–1.1) 0.81 (0.53–1.0) 0.89
Weight gain per week after GDM diagnosis (pounds) 0.56 (0.15–0.89) 0.67 (0.31–1.0) 0.047
Overall weight gain per week 0.70 (0.44–0.97) 0.79 (0.55–1.0) 0.06
Treatment 0.79
Insulin plus diet 59 (45.0) 45 (43.3)
Diet only 72 (55.0) 59 (56.7)
Data are presented as median (interquartile range) or n (%).
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gain, despite being statistically significant, given that this
translates to an increase in weight of only 1–2 pounds by the
end of the pregnancy. It is unclear why patients in the one-
step method group would have more weight gain than patients
in the two-step method group after being diagnosed with
GDM, but this association warrants further investigation.
Nevertheless, patients in the one-step method group were also
more likely to have an ultrasonographic suspicion of
macrosomia before delivery as well as an infant 44000 g
than the two-step method patients, although these differences
were not statistically significant. Thus, the increase in weight
gain may partially explain the increased risk for macrosomia
seen in these patients.
It also should be noted that the patients diagnosed with the
one-step method had significantly more ultrasounds than
those diagnosed with the two-step method. This may explain
why there were more patients with suspected fetal macro-
somia in the one-step group. The difference in frequency of
ultrasounds is not explained by the baseline characteristics
of the two groups. We were missing data on the number of
ultrasounds for more than 20% of the patients in each group,
so further studies are warranted to see if this difference
persists in other similar cohorts.
Strengths of this study included a diverse racial and ethnic
demographic, and except for the ultrasound data mentioned
above, there was very little missing data from the review of
the patients’ medical records. We only included patients from
one academic institution in one geographic area. This can be
considered as a strength of the study in that pregnancy
management was fairly consistent during these two time
periods, especially given that almost all GDM patients were
managed by the JDC. Though it may also be considered a
weakness because our findings are not necessarily generaliz-
able to patients in other regions. The study did have several
other limitations. The study population was a sample of
convenience, chosen to allow for approximately one year
before and after implementation of the new testing guidelines.
Therefore, we did not perform an a priori sample size
calculation. A post-hoc power calculation was performed to
assess if there was enough power to detect a difference in
macrosomia between the two groups. We determined that we
only had 32% power to detect the difference of the observed
magnitude. Thus, our sample size limited our ability to detect
potentially clinically meaningful differences in outcomes
between the two groups. This study was not designed to assess
the expected change in GDM incidence with the one-step
IADPSG method so we were not able to determine if
implementing these new guidelines increased the number of
women being diagnosed with GDM, which is the concern
articulated by ACOG.
Our findings demonstrate that women diagnosed with
GDM by the one-step method had a similarly high prevalence
of GDM risk factors as women diagnosed by the two-step
method. These data thus address concerns in the literature and
among professional societies that the one-step IADPSG
screening guidelines may identify a lower-risk group of
women as having GDM, increasing their anxiety and
increasing health care costs with more visits, more ultra-
sounds, additional laboratory testing, and no clear indication
of the benefit [13,14]. In fact, patients diagnosed using the
one-step method gained more weight per week after the GDM
diagnosis, and had a trend towards higher risk for suspected
macrosomia than the group diagnosed using the traditional
two-step method. Our data suggest that the one-step IADPSG





Number of ultrasounds* 8.0 (5.0–11.0) 9.5 (7.0–12.0) 0.003
Gestational age at delivery (weeks) 39.0 (37.9–39.7) 39.0 (38.0–39.6) 0.99
Delivery type 0.64
Spontaneous vaginal 68 (51.9) 52 (50.0)
Cesarean 63 (48.1) 51 (49.0)
Vacuum-assisted vaginal 0 (0.0) 1 (1.0)
Pregnancy complications
Hypertensive disordery 21 (16.0) 17 (16.3) 0.95
Polyhydramnios 1 (0.8) 2 (1.9) 0.58
IUGR 10 (7.6) 4 (3.8) 0.22
Suspected macrosomia 7 (5.3) 12 (11.5) 0.08
Shoulder dystocia 0 (0.0) 1 (1.0) 0.44
Other 14 (10.7) 5 (4.8) 0.10
Birth weight (g) 3295.0 (2995.0–3590.0) 3320.0 (2970.0–3622.5) 0.54
Weight44000 g 10 (7.6) 14 (13.5) 0.14
NICU Admission 23 (18.0) 12 (11.5) 0.17
Neonatal complications
Neonatal hypoglycemia 8 (6.1) 3 (2.9) 0.35
Hyperbilirubinemia 11 (8.4) 9 (8.7) 0.94
Birth injury (clavicle fracture, brachial plexus injury) 0 (0.0) 0 (0.0) –
Any neonatal adverse outcomez 35 (26.7) 27 (26.0) 0.90
IUGR¼intrauterine growth restriction; NICU¼neonatal intensive care unit. Data are presented as median (interquartile
range) or n (%).
*Twenty-nine (22.1%) women in the two-step method group and 22 (21.2%) in the one-step method group were missing
data on the number of ultrasounds in pregnancy.
yIncludes gestational hypertension, preeclampsia and hemolysis, elevated liver enzymes, low platelets.
zAny neonatal adverse outcome includes macrosomia, hypoglycemia, birth injury, hyperbilirubinemia or NICU admission.
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method identifies women with at least equally high risk as the
two-step method. Given that we compared different methods
of diagnosis, we do not make any recommendations about
clinical care based on our study. Indeed, it is important to
evaluate whether treatment of women diagnosed with the one-
step method will influence outcomes, and this is an aim for a
future study. As additional, large-scale, multi-center studies
are being done, our institution and all obstetric providers
worldwide await further data and recommendations from
national and international organizations.
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